{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Immune System Regulation in Cardiovascular Diseases"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This randomised controlled trial was conducted with participants meeting specific eligibility criteria at a designated clinical setting."
      },
      "Participants": {
        "score": 2,
        "evidence": "participants meeting specific eligibility criteria at a designated clinical setting"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomly assigned to receive either the intervention or a control treatment."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aims to evaluate the efficacy of immune-targeted therapies in CVDs."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the reduction in cardiovascular events, measured over a 12-month period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, with allocation concealment ensured through sealed envelopes."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was applied to outcome assessors, patients, and clinicians."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised: 100 to the intervention group and 100 to the control group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on 98 participants in the intervention group and 97 in the control group using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group showed a significant reduction in cardiovascular events compared to the control group (mean difference = 5.2 events, 95% CI 3.1 to 7.3; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were reported in 3% of the intervention group and 1% of the control group, with mild gastrointestinal side-effects."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "This trial was funded by the National Institutes of Health."
      }
    },
    "total_score": 25,
    "max_score": 25
  },
  "model": "gpt-4o"
}